Weekly Insulin Injection ‘Awiqli’ Launching Soon in Canada
Introduction
Canada is set to be the first country to introduce the world’s first weekly insulin injection, Awiqli, offering significant relief to people with diabetes.
Overview
- Product: Insulin icodec, branded as Awiqli.
- Manufacturer: Novo Nordisk.
- Launch Date: June 30, 2024.
- Approval: Approved by Health Canada in March 2024.
Benefits for Patients
- Reduced Injection Frequency: Awiqli allows for once-a-week injections instead of daily shots.
- Patient Impact:
- Particularly beneficial for Type 2 diabetes patients who struggle with daily injections.
- May improve adherence to insulin therapy, reducing long-term complications like eye, kidney, and heart diseases.
- Clinical Trials:
- Primarily focused on Type 2 diabetes patients.
- Showed a higher risk of low blood sugar in Type 1 diabetes patients, who still need daily fast-acting insulin at mealtimes.
Expert Opinions
- Dr. Harpreet Bajaj:
- Called it a “big deal” for reducing the burden on diabetes patients.
- Mentioned patient anticipation due to participation in clinical trials.
- Dr. Alexander Abitbol:
- Highlighted the potential for improved patient compliance.
- Cautioned that Awiqli might not suit every diabetes patient but is a valuable option for suitable cases.
Cost and Accessibility
- Price Concerns:
- Estimated to cost over $1,350 per year per patient.
- Daily insulin shots are less expensive due to longer availability and lack of patents.
- Funding and Reimbursement:
- Canada’s Drug Agency recommends Awiqli for Type 2 diabetes with price adjustments.
- Private insurers’ coverage remains uncertain, but initial positive signals are reported.
Special Considerations for Type 1 Diabetes
- Limited Use:
- Awiqli may still benefit certain Type 1 patients who are non-compliant with daily insulin or have special needs.
- Trial Findings:
- Higher risk of low blood sugar was observed, necessitating cautious use.
Conclusion
Awiqli’s introduction in Canada marks a significant advancement in diabetes care, offering a more convenient option for insulin-dependent patients. While it promises to ease the treatment regimen, cost and individual patient suitability remain critical factors to address. As Canada leads the way with this innovative treatment, it paves the path for potential global adoption, contingent on further studies and approvals.